RestructuringJul 14, 2026, 04:22 PM
Baxter Restructures Reporting Segments, Recasts Financials
AI Summary
Baxter International Inc. has restructured its operating model, changing its reportable segments from three to two, effective Q2 2026. The new segments are Medical Products & Therapies (MPT) and Healthcare Systems & Technologies (HST), with the former Pharmaceuticals segment now integrated into MPT. The company is furnishing recast historical financial information for comparability, which does not impact previously reported consolidated net income or EPS.
Key Highlights
- Restructured from three to two reportable segments, effective Q2 2026.
- New segments are Medical Products & Therapies (MPT) and Healthcare Systems & Technologies (HST).
- Former Pharmaceuticals segment now integrated into MPT's Infusion Therapies & Platforms division.
- Recast historical segment financial data provided for Q1 2026, 2025, and 2024.
- MPT 2025 total sales reported as $7,843 million.
- HST 2025 total sales reported as $3,071 million.
- Q1 2026 MPT total sales were $1,920 million, HST total sales $705 million.
- Consolidated net income, EPS, and total assets are unaffected by the changes.
Price Impact
More from BAX